PDS Biotechnology (NASDAQ:PDSB) Stock Price Breaks Below Two Hundred Day Moving Average - Time to Sell?

PDS Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • PDS Biotechnology shares fell below their 200-day moving average of $0.84, trading as low as $0.762 and last at $0.7841; the 50-day average was $1.02.
  • Analyst opinions were mixed: two analysts rated the stock Buy and one Sell, while MarketBeat reported an average rating of Hold and an average price target of $9.50.
  • The clinical-stage cancer immunotherapy company reported a quarterly loss of $0.11 per share, missing the $0.09 loss estimate by $0.02.
  • Five stocks to consider instead of PDS Biotechnology.

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.84 and traded as low as $0.7620. PDS Biotechnology shares last traded at $0.7841, with a volume of 4,266,077 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PDSB shares. Wall Street Zen raised PDS Biotechnology from a "sell" rating to a "hold" rating in a report on Monday, October 5th. Weiss Ratings raised PDS Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, September 28th. HC Wainwright restated a "buy" rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Finally, B. Riley Financial restated a "buy" rating and set a $4.00 price objective (up from $3.00) on shares of PDS Biotechnology in a research note on Thursday, October 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.50.

Check Out Our Latest Analysis on PDS Biotechnology

PDS Biotechnology Stock Performance

The stock has a market cap of $43.89 million, a price-to-earnings ratio of -1.40 and a beta of 1.16. The company's 50 day simple moving average is $1.02 and its 200 day simple moving average is $0.84. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). On average, equities research analysts anticipate that PDS Biotechnology Corporation will post -0.41 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $535,000. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the third quarter valued at approximately $210,000. Tocqueville Asset Management L.P. acquired a new stake in PDS Biotechnology during the third quarter valued at approximately $130,000. Provenance Wealth Advisors LLC bought a new stake in PDS Biotechnology during the third quarter worth approximately $59,000. Finally, Bank of New York Mellon Corp bought a new stake in PDS Biotechnology during the second quarter worth approximately $60,000. Institutional investors and hedge funds own 26.84% of the company's stock.

About PDS Biotechnology

(Get Free Report)

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing immunotherapies designed to stimulate the immune system to fight cancer. The company's research focuses on treatments for HPV-associated cancers and other solid tumors. Its pipeline includes PDS0101, an investigational immunotherapy targeting cancers associated with human papillomavirus 16 (HPV16). The candidate uses the company's Versamune platform and is being studied in clinical trials, including in combination with other cancer treatments.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PDS Biotechnology Right Now?

Before you consider PDS Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.

While PDS Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines